481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Saved in:
Bibliographic Details
Title: 481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN
Authors: Vierling, J.M., Lawitz, E.J., Poordad, F., Sulkowski, M.S., Bourliere, M., Buti, M., Cooper, C., Galati, J.S., Albrecht, J.K., Boparai, N., Brass, C.A., Burroughs, M., Sniukiene, V., Bruno, S.
Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS197-S197. 1p.
Database: Academic Search Ultimate
Description
ISSN:01688278
DOI:10.1016/S0168-8278(11)60483-2